专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016011169A1 HYDROGEN ABSTRACTION FROM ALKANES USING HYDROGEN STORAGE MATERIALS 审中-公开
标题翻译：使用氢储存材料从碱中萃取氢
公开(公告)号：WO2016011169A1
公开(公告)日：2016-01-21
申请号：PCT/US2015/040599
申请日：2015-07-15
申请人： SABIC GLOBAL TECHNOLOGIES B.V. , MITCHELL, Scott, F. , CONANT, Travis, R. , GRABOW, Lars, C.
发明人： MITCHELL, Scott, F. , CONANT, Travis, R. , GRABOW, Lars, C.
IPC分类号： C07C2/84 , C07C2/76 , C07C9/06
CPC分类号： C07C2/76 , C07C5/42 , C07C2521/06 , C07C9/06 , C07C11/06
摘要： Disclosed is a method for making C 2 or larger hydrocarbons from methane or for dehydrogenating C 2 or larger hydrocarbons. The method can include contacting methane or C 2 or larger hydrocarbons with a hydridable material under reaction conditions sufficient to effect removal of at least one hydrogen atom from a plurality of methane molecules or C 2 or larger hydrocarbons to produce a plurality of methyl radicals or to dehydrogenate the C 2 or larger hydrocarbons. With respect to the produced plurality of methyl radicals, they can combine together to form C 2 or larger hydrocarbons. The reaction is performed in the absence of oxygen gas and reactive metal oxides.
摘要翻译：公开了一种从甲烷制备C2或更大的烃或用于使C2或更大的烃脱氢的方法。该方法可以包括在足以从多个甲烷分子或C2或更大的烃去除至少一个氢原子的反应条件下将甲烷或C2或更大的烃与可混合的物质接触以产生多个甲基或脱氢 C2或更大的烃。对于所生产的多个甲基，它们可以组合在一起形成C2或更大的烃。反应在没有氧气和反应性金属氧化物的情况下进行。

2. 发明申请

WO2013040376A2 DATA PROVISIONING SYSTEM AND METHOD 审中-公开
标题翻译：数据提供系统及方法
公开(公告)号：WO2013040376A2
公开(公告)日：2013-03-21
申请号：PCT/US2012/055450
申请日：2012-09-14
申请人： GENERAL ELECTRIC COMPANY , ELDER, Michael, Stephen , WEINDORF, Timothy, C , MUAYDH, Ahmed, M , WILLS, Mitchell, Scott , WOOD, Brandi, Elizabeth
发明人： ELDER, Michael, Stephen , WEINDORF, Timothy, C , MUAYDH, Ahmed, M , WILLS, Mitchell, Scott , WOOD, Brandi, Elizabeth
IPC分类号： G06Q10/06
CPC分类号： G06Q10/00 , G05B15/00 , G06Q10/0831 , G06Q10/0834 , G06Q50/06 , Y04S10/56
摘要： Systems (1) and methods (20, 30) providing an application (5) having one or more management modules, wherein at least one management module is configured to display a metric value, and wherein the metric value is obtained by the application (5) based on a query of a database (6) containing information about a fleet of assets (12). Embodiments of the present invention provide information to an end user in response to the end user's request regarding one or more assets from the fleet of assets (12). The requests may include aspects of fleet performance, and individual assets within the fleet, and may relate to energy consumption, asset health or repair status, or movement through a network.
摘要翻译：提供具有一个或多个管理模块的应用（5）的系统（1）和方法（20,30），其中至少一个管理模块被配置为显示度量值，并且其中度量值由应用程序（5 ）基于包含关于资产队列（12）的信息的数据库（6）的查询。本发明的实施例向最终用户提供响应于终端用户关于来自资产队列（12）的一个或多个资产的请求的信息。这些请求可能包括车队绩效的方面以及车队内的个人资产，并且可能涉及能源消耗，资产健康或维修状态，或通过网络的移动。

3. 发明申请

WO2010068257A1 IMIDAZOPYRAZINE SYK INHIBITORS 审中-公开
标题翻译：咪唑吡嗪SYK抑制剂
公开(公告)号：WO2010068257A1
公开(公告)日：2010-06-17
申请号：PCT/US2009/006445
申请日：2009-12-07
申请人： CGI PHARMACEUTICALS, INC. , MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , KROPF, Jeffrey E. , LEE, Seung H. , XU, Jianjun , STAFFORD, Douglas G. , HARDING, James P. , BARBOSA, Jr., Antonio J. , ZHAO, Zhongdong
发明人： MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , KROPF, Jeffrey E. , LEE, Seung H. , XU, Jianjun , STAFFORD, Douglas G. , HARDING, James P. , BARBOSA, Jr., Antonio J. , ZHAO, Zhongdong
IPC分类号： A01N43/60 , A61K31/495
CPC分类号： C07D487/04 , A61K31/495 , C07D471/04 , C07D491/107 , C07D498/04 , C07D519/00 , C12Q1/485 , G01N33/573 , G01N2333/91205
摘要： Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
摘要翻译：本文提供了某些咪唑并嗪及其药物组合物。治疗患有某些对抑制Syk活性有作用的疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症体征或症状的化学实体。还提供了用于确定样品中Syk激酶的存在或不存在的方法。

4. 发明申请

WO2009102468A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF 审中-公开
标题翻译： 6-ARYL-IMIDAZO [L，2-A]吡嗪衍生物，制备方法及其使用方法
公开(公告)号：WO2009102468A1
公开(公告)日：2009-08-20
申请号：PCT/US2009/000919
申请日：2009-02-12
申请人： CGI PHARMACEUTICALS, INC. , MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , ARMISTEAD, David M. , RAKER, Joseph
发明人： MITCHELL, Scott A. , CURRIE, Kevin S. , BLOMGREN, Peter A. , ARMISTEAD, David M. , RAKER, Joseph
IPC分类号： C07D487/04 , A61K31/4985 , A61P37/00
CPC分类号： C07D487/04
摘要： Certain chemical entities chosen from compounds represented by Formula I and pharmaceutically acceptable salts and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer (e.g., B -cell lymphoma and leukemia), autoimmune diseases, inflammatory diseases, acute inflammatory reactions, and allergic disorders. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for determining the presence or absence of Syk kinase in a sample. Formula I
摘要翻译：在本文中提供了选自由式I表示的化合物的某些化学实体及其药学上可接受的盐及其混合物。包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。公开了治疗患有对抑制Syk活性有反应的某些疾病和病症的患者的方法，所述方法包括向所述患者施用一定量的至少一种有效减少疾病或病症体征或症状的化学实体。这些疾病包括癌症（例如，B细胞淋巴瘤和白血病），自身免疫疾病，炎性疾病，急性炎症反应和过敏性疾病。治疗方法包括给予至少一种化学实体作为单一活性剂或与一种或多种其它治疗剂组合施用至少一种化学实体。还提供了用于确定样品中Syk激酶的存在或不存在的方法。一级方程式

5. 发明申请

WO2008082534A2 REGENERATION OF PLATINUM-GERMANIUM ZEOLITE CATALYST 审中-公开
标题翻译：铂 - 锗沸石催化剂的再生
公开(公告)号：WO2008082534A2
公开(公告)日：2008-07-10
申请号：PCT/US2007/025875
申请日：2007-12-19
申请人： SAUDI BASIC INDUSTRIES CORPORATION , ELLIS, Paul, E. , JUTTU, Gopalakrishnan, G. , KHANMAMEDOVA, Alla, K. , MITCHELL, Scott, F. , STEVENSON, Scott, A.
发明人： ELLIS, Paul, E. , JUTTU, Gopalakrishnan, G. , KHANMAMEDOVA, Alla, K. , MITCHELL, Scott, F. , STEVENSON, Scott, A.
IPC分类号： C07C15/00 , B01J20/34
CPC分类号： B01J29/90 , B01J29/068 , B01J29/44 , B01J38/06 , B01J38/10 , B01J38/18 , B01J38/42 , B01J2229/183 , B01J2229/186 , B01J2229/42 , C07C2/00 , C07C2/76 , C07C2529/74 , Y02P20/584 , Y02P20/588 , Y10S585/904 , C07C15/00
摘要： This invention relates to a process for regeneration of a zeolite catalyst, specifically an aluminosilicate zeolite with germanium substituted in the framework for silicon and with platinum deposited on the zeolite. The catalyst may be used in a process for aromatization of alkanes, specifically C 2 -C 8 alkanes. The regeneration process 1 ) removes coke and sulfur from the catalyst via oxidation, 2) redisperses platinum on the surface of the catalyst via chlorine gas, 3) removes chlorine and bind Pt to the surface of the zeolite by steaming, 4) reduces the catalyst in hydrogen, and 5) optionally, resulfides the catalyst. The zeolite may be a MFI zeolite. The catalyst may be bound with an inert material which does not act as a binding site for platinum during the regeneration process, for example, silica.
摘要翻译：本发明涉及一种沸石催化剂的再生方法，具体地说是一种在硅骨架中取代了锗的硅铝酸盐沸石，其中铂沉积在沸石上。该催化剂可以用于烷烃，特别是C 2 -C 8烷烃的芳构化方法中。再生过程1）通过氧化从催化剂中除去焦炭和硫，2）通过氯气将催化剂表面上的铂再分散，3）除去氯并通过汽蒸将Pt结合到沸石的表面上，4）减少催化剂在氢气中，和5）任选地使催化剂再硫化。沸石可以是MFI沸石。催化剂可以与在再生过程中不作为铂结合位点的惰性材料结合，例如二氧化硅。

6. 发明申请

WO2007089532A1 METHOD FOR CONGESTION MANAGEMENT IN A RAILWAY SYSTEM 审中-公开
标题翻译：铁路系统中控制管理的方法
公开(公告)号：WO2007089532A1
公开(公告)日：2007-08-09
申请号：PCT/US2007/002006
申请日：2007-01-20
申请人： GENERAL ELECTRIC COMPANY , KICKBUSCH, Joel , MARKLEY, Randall , WILLS, Mitchell, Scott , PHILP, Joseph, Wesley
发明人： KICKBUSCH, Joel , MARKLEY, Randall , WILLS, Mitchell, Scott , PHILP, Joseph, Wesley
IPC分类号： B61L27/00
CPC分类号： B61L27/0027 , B61L27/0011
摘要： A scheduling system and method for moving plural objects through a multipath system described as a freight railway scheduling system. The scheduling system utilizes a cost reactive resource scheduler to minimize resource exception while at the same time minimizing the global costs associated with the solution. The achievable movement plan can be used to assist in the control of, or to automatically control, the movement of trains through the system. Deadlock is avoided by controlling the entry of trains into congested areas, and may be automatically implemented by the use of traffic flow analysis algorithms.
摘要翻译：一种用于通过描述为货运铁路调度系统的多路径系统移动多个物体的调度系统和方法。调度系统利用成本反应性资源调度器来最小化资源异常，同时最小化与解决方案相关联的全局成本。可实现的运动计划可用于协助控制或自动控制列车通过系统的运动。通过控制火车进入拥堵区域来避免死锁，并且可以通过使用交通流量分析算法自动实现。

7. 发明申请

WO2005110416A3 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES 审中-公开
公开(公告)号：WO2005110416A3
公开(公告)日：2006-04-13
申请号：PCT/US2005015897
申请日：2005-05-06
申请人： NEUROGEN CORP , MAYNARD GEORGE D , GHOSH MANUKA , YUAN JUN , CURRIE KEVIN S , MITCHELL SCOTT , GUO QIN , ZHAO HE
发明人： MAYNARD GEORGE D , GHOSH MANUKA , YUAN JUN , CURRIE KEVIN S , MITCHELL SCOTT , GUO QIN , ZHAO HE
IPC分类号： A61K31/505 , C07D239/26 , C07D239/28 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D417/04 , C07D471/04 , C07D498/04 , A61K31/506 , C07D43/04
CPC分类号： A61K31/505 , C07D239/26 , C07D239/28 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D417/04 , C07D471/04 , C07D498/04
摘要： 4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.
摘要翻译：提供式（I）和式（II）的4,5-二取代-2-芳基嘧啶：其中R 1，R 2，R 3， R 8，R 8，R 9，A和Ar如本文所定义。这些化合物是C5a受体的配体。优选的式I和II化合物以高亲和力结合C5a受体，并在C5a受体上呈现中性拮抗剂或反向活性。本发明还涉及包含这些化合物的药物组合物，以及这些化合物在治疗各种炎性，心血管和免疫系统疾病中的用途。此外，本发明提供标记的4,5-二取代-2-芳基嘧啶，其可用作C5a受体定位的探针。

8. 发明申请

WO2005110416A2 4,5-DISUBSTITUTED-2-ARYL PYRIMIDINES 审中-公开
标题翻译： 4,5-取代的2-芳基吡啶
公开(公告)号：WO2005110416A2
公开(公告)日：2005-11-24
申请号：PCT/US2005/015897
申请日：2005-05-06
申请人： NEUROGEN CORPORATION , MAYNARD, George, D. , GHOSH, Manuka , YUAN, Jun , CURRIE, Kevin, S. , MITCHELL, Scott , GUO, Qin , ZHAO, He
发明人： MAYNARD, George, D. , GHOSH, Manuka , YUAN, Jun , CURRIE, Kevin, S. , MITCHELL, Scott , GUO, Qin , ZHAO, He
IPC分类号： A61K31/505
CPC分类号： A61K31/505 , C07D239/26 , C07D239/28 , C07D239/34 , C07D239/42 , C07D239/47 , C07D239/48 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D417/04 , C07D471/04 , C07D498/04
摘要： 4,5-disubstituted-2-arylpyrimidines of Formula (I) and Formula (II) are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.
摘要翻译：提供式（I）和式（II）的4,5-二取代-2-芳基嘧啶：其中R 1，R 2，R 3，R 8，R 9，A和Ar如本文所定义。这些化合物是C5a受体的配体。优选的式I和II化合物以高亲和力结合C5a受体，并在C5a受体上呈现中性拮抗剂或反向活性。本发明还涉及包含这些化合物的药物组合物，以及这些化合物在治疗各种炎性，心血管和免疫系统疾病中的用途。此外，本发明提供标记的4,5-二取代-2-芳基嘧啶，其可用作C5a受体定位的探针。

9. 发明申请

WO2005065393A3 PROCESS FOR ALKANE AROMATIZATION USING PLATINUM-ZEOLITE CATALYST 审中-公开
公开(公告)号：WO2005065393A3
公开(公告)日：2005-07-21
申请号：PCT/US2004/043983
申请日：2004-12-30
申请人： SAUDI BASIC INDUSTRIES CORPORATION , MITCHELL, Scott, F. , JUTTU, Gopalakrishnan, G. , SMITH, Robert, Scott
发明人： MITCHELL, Scott, F. , JUTTU, Gopalakrishnan, G. , SMITH, Robert, Scott
IPC分类号： C07C2/52
摘要： Aromatization of alkanes having one to four carbon atoms per molecule to aromatics, such as benzene, toluene and xylenes (BTX), uses a catalyst of a crystalline zeolite on which platinum has been deposited, specifically a platinum-containing ZSM-5. A byproduct of the process is a light gas fraction of methane and ethane. The use of a platinum-containing ZSM-5 catalyst in an alkane aromatization process, such as the Cyclar process, suppresses the formation of methane and increases selectivity to BTX. The high content of ethane relative to methane in the light gas fraction allows this process effluent to be a feedstream for a cracker .

10. 发明申请

WO2005019220A9 SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY 审中-公开
标题翻译：取代的咪唑并[1,2-a]吡嗪类化合物作为激酶活性的调节剂
公开(公告)号：WO2005019220A9
公开(公告)日：2005-06-02
申请号：PCT/US2004025884
申请日：2004-08-11
申请人： CELLULAR GENOMICS INC , MITCHELL SCOTT A , DESIMONE ROBERT W , DARROW JAMES W , PIPPIN DOUGLAS A , DANCA M DIANA
发明人： MITCHELL SCOTT A , DESIMONE ROBERT W , DARROW JAMES W , PIPPIN DOUGLAS A , DANCA M DIANA
IPC分类号： A61K31/498 , A61P35/00 , C07D487/04 , A61K31/4985
CPC分类号： C07D487/04
摘要： Certain substituted imidazo[1,2-a]pyrazines and the pharmaceutically-acceptable salts thereof, are provided herein. Pharmaceutical compositions containing one or more compound of Formula I, or a pharmaceutically acceptable salt of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to EphB4 kinase modulation, which comprise administering to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Thus methods of treatment include administering a sufficient amount of a compound of the invention to decrease the symptoms or slow the progression of these diseases or disorders. Methods of treatment include administering a compound of Formula I as a single active agent or administering a compound of Formula I in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with a compound of Formula I under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
摘要翻译：本文提供了某些取代的咪唑并[1,2-a]吡嗪及其药学上可接受的盐。本文还提供了含有一种或多种式I化合物或这些化合物的药学上可接受的盐以及一种或多种药学上可接受的载体，赋形剂或稀释剂的药物组合物。公开了治疗患有对EphB4激酶调节有响应的某些疾病和病症的患者的方法，其包括向所述患者施用有效减少疾病或病症的体征或症状的量的式I化合物。这些疾病包括癌症，包括乳腺瘤，子宫内膜癌，结肠癌和颈部鳞状细胞癌。因此治疗方法包括给予足够量的本发明化合物以减轻这些疾病或病症的症状或减缓其进展。治疗方法包括施用式I化合物作为单一活性剂或将式I化合物与一种或多种其他治疗剂组合施用。用于确定样品中血管生成激酶的存在或不存在的方法，包括在允许检测血管生成激酶活性，检测血管生成激酶活性水平的条件下使样品与式I化合物接触，并由此确定样品中血管生成激酶的存在或不存在。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式